pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER
Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
ASP3082, DEXTROSE INJECTION / BRADEX 5%
Phase 2 · small molecule · Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma
ASP3082, DEXTROSE INJECTION / BRADEX 5% for Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Internal code CSET 2025/4116
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- The George Institute
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma
- Status
- active
- Trials
- 1